Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RemeGen | Shanghai | Healthcare | Biotechnology & Medical Research | 127.3% | CN¥3.58KCr | -16.5x | -2.34 | CN¥71 | 17.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -35.2% Downside | Upgrade to Pro+ | |
Sichuan Biokin Pharmaceutical | Shanghai | Healthcare | Pharmaceuticals | 60.3% | CN¥13.53KCr | 35.8x | 0.06 | CN¥337.50 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -9% Downside | Upgrade to Pro+ | |
SBT Ultrasonic Tech | Shanghai | Industrials | Machinery, Tools, Heavy Vehicles, Trains & Ships | 55.2% | CN¥2.57KCr | -57.9x | -2.97 | CN¥52.92 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -57.4% Downside | Upgrade to Pro+ | |
InnoCare Pharma | Shanghai | Healthcare | Biotechnology & Medical Research | 53.3% | CN¥2.57KCr | -57.9x | -3.37 | CN¥27.29 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dizal Jiangsu Pharmaceutical | Shanghai | Healthcare | Biotechnology & Medical Research | 45.5% | CN¥3.05KCr | -28.5x | -1.41 | CN¥66.33 | 6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.5% Upside | Upgrade to Pro+ | |
Ruida | Shenzhen | Financial | Investment Banking & Investment Services | 40.4% | CN¥884Cr | 18.4x | 0.46 | CN¥19.87 | 10% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -40.6% Downside | Upgrade to Pro+ | |
Suzhou Zelgen Biopharma | Shanghai | Healthcare | Pharmaceuticals | 37.3% | CN¥3.22KCr | -200x | -4.91 | CN¥121.48 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.1% Upside | Upgrade to Pro+ | |
Chongqing Genrix Biopharmaceutical | Shanghai | Healthcare | Pharmaceuticals | 35.8% | CN¥1.14KCr | -15x | -1.88 | CN¥31.21 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.4% Upside | Upgrade to Pro+ | |
Shanghai Allist Pharmaceuticals Co | Shanghai | Healthcare | Biotechnology & Medical Research | 24.7% | CN¥4.32KCr | 0.41 | CN¥96.01 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.2% Upside | Upgrade to Pro+ | ||
Beigene | Shanghai | Healthcare | Biotechnology & Medical Research | 23.6% | CN¥23.98KCr | -61.7x | -1.8 | CN¥267.40 | 8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.3% Upside | Upgrade to Pro+ | |
Holly Futures | Shenzhen | Financial | Investment Banking & Investment Services | 16.7% | CN¥906Cr | 50.8x | 0.41 | CN¥10.83 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jiangsu Asieris Pharmaceuticals | Shanghai | Healthcare | Biotechnology & Medical Research | 11% | CN¥533Cr | -13.1x | -1.67 | CN¥9.50 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
Huaxi Securities A | Shenzhen | Financial | Investment Banking & Investment Services | 1.8% | CN¥2.26KCr | 25.7x | 0.05 | CN¥8.62 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.7% Upside | Upgrade to Pro+ | |
Beijing Compass | Shenzhen | Technology | Financial Technology (Fintech) & Infrastructure | 1.4% | CN¥3.72KCr | 158x | 0.29 | CN¥62.25 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -37.1% Downside | Upgrade to Pro+ | |
Dongxing Securities | Shanghai | Financial | Investment Banking & Investment Services | -7% | CN¥3.57KCr | 20.8x | 0.37 | CN¥11.03 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -22.9% Downside | Upgrade to Pro+ | |
Guolian Securities Co | Shanghai | Financial | Investment Banking & Investment Services | -8.8% | CN¥5.45KCr | 11.2x | 0.23 | CN¥10.11 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.1% Upside | Upgrade to Pro+ |